At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 110 target
Drug / intervention
ZG19018drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Dose Escalation and Expansion Study to Evaluating the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
In Brief
A Phase 2 clinical trial evaluating ZG19018 for KRAS G12C Mutant Advanced Solid Tumors. Targeting 110 participants across 1 site.
Detailed Summary
Evaluate the safety and tolerability of ZG19018 in Patients with KRAS G12C mutant advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKRAS G12C Mutant Advanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2023202420252026
Enrollment StartMay 2022
First PostedFeb 2024
Primary CompletionMay 2025
TodayJul 2026
First PostedFeb 1, 2024
Enrollment StartMay 26, 2022
Primary CompletionMay 1, 2025
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 2.4 years ago
Interventions
ZG19018drug
ZG19018 Given by PO (mouth)